Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08NZG
|
|||
| Drug Name |
Ifabotuzumab
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 2 | [1] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [2], [3] | ||
| Company |
Humanigen Brisbane, CA Olivia Newton-John Cancer Research Institute Heidelberg, Australia
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ephrin type-A receptor 3 (EPHA3) | Target Info | Antagonist | [1], [2] |
| KEGG Pathway | Axon guidance | |||
| Pathway Interaction Database | EphrinA-EPHA pathway | |||
| EPHA forward signaling | ||||
| Reactome | EPH-Ephrin signaling | |||
| EPHA-mediated growth cone collapse | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.